{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:32:24Z","timestamp":1787668344445,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"DOI":"10.1007\/s11481-025-10272-9","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:43:24Z","timestamp":1767426204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Telitacicept as a New Therapeutic Avenue for Generalized Myasthenia Gravis and Thymoma-Associated Myasthenia Gravis"],"prefix":"10.1007","volume":"21","author":[{"given":"Ying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benqiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"8","key":"10272_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA et al (2020) Comparison between Rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 77(8):974\u2013981","journal-title":"JAMA Neurol"},{"issue":"1","key":"10272_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","volume":"82","author":"X Chen","year":"2016","unstructured":"Chen X, Zhao Q, Hou Y et al (2016) Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS\/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol 82(1):41\u201352","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10272_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus 32(1):94\u2013100","journal-title":"Lupus"},{"issue":"6","key":"10272_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, Duda PW, Kaminski HJ (2019) Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve 60(6):707\u2013715","journal-title":"Muscle Nerve"},{"issue":"3","key":"10272_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S (2018) Eculizumab: a review in generalized myasthenia gravis. Drugs 78(3):367\u2013376","journal-title":"Drugs"},{"issue":"14","key":"10272_CR6","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81(14):1671\u20131675","journal-title":"Drugs"},{"key":"10272_CR7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A et al (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776","journal-title":"Front Immunol"},{"issue":"2","key":"10272_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A (2025) New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs 39(2):185\u2013213","journal-title":"BioDrugs"},{"key":"10272_CR9","unstructured":"Germinal centers are associated with postthymectomy myasthenia gravis in patients with thymoma; Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy, Mod. Pathol.: an Official Journal of the United States and Canadian Academy of Pathology, Inc (2022)."},{"key":"10272_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"issue":"2","key":"10272_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149","journal-title":"Muscle Nerve"},{"issue":"12","key":"10272_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986","journal-title":"Lancet Neurol"},{"issue":"7","key":"10272_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, ADAPT Investigator Study Group (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536","journal-title":"Lancet Neurol"},{"key":"10272_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/mus.26300","volume":"58","author":"H Kim","year":"2018","unstructured":"Kim H, Lim Y-M, Lee E-J et al (2018) Factors predicting remission in thymectomized patients with acetylcholine receptor antibody positive myasthenia gravis. Muscle Nerve 58:796\u2013800","journal-title":"Muscle Nerve"},{"issue":"10","key":"10272_CR15","doi-asserted-by":"publisher","first-page":"102646","DOI":"10.1016\/j.autrev.2020.102646","volume":"19","author":"I Koneczny","year":"2020","unstructured":"Koneczny I (2020) Update on IgG4-mediated autoimmune diseases: new insights and new family members. Autoimmun Rev 19(10):102646","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10272_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.27659","volume":"66","author":"I Lee","year":"2022","unstructured":"Lee I, Leach JM, Aban I, McPherson T, Duda PW, Cutter G (2022) One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG patient registry. Muscle Nerve 66(4):411\u2013420","journal-title":"Muscle Nerve"},{"issue":"17","key":"10272_CR17","doi-asserted-by":"publisher","first-page":"175628642412514","DOI":"10.1177\/17562864241251476","volume":"14","author":"J Lin","year":"2024","unstructured":"Lin J, Li Y, Gui M, Bu B, Li Z (2024) Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study. Ther Adv Neurol Disord 14(17):17562864241251476","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"10272_CR18","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol 263(8):1473\u20131494","journal-title":"J Neurol"},{"key":"10272_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1756285611411503","volume":"4","author":"RJ Nowak","year":"2011","unstructured":"Nowak RJ, Dicapua DB, Zebardast N et al (2011) Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 4:259\u2013266","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10272_CR20","first-page":"e376","volume":"98","author":"RJ Nowak","year":"2021","unstructured":"Nowak RJ, Coffey CS, Goldstein JM et al (2021) Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG Study. Neurology 98(4):e376\u2013e389","journal-title":"Neurology"},{"issue":"6","key":"10272_CR21","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B, Myasthenia Gravis Study Group (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50(6):1778\u20131783. https:\/\/doi.org\/10.1212\/WNL.50.6.1778","journal-title":"Neurology"},{"issue":"14","key":"10272_CR22","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","volume":"97","author":"M Petersson","year":"2021","unstructured":"Petersson M, Feresiadou A, Jons D, Ilinca A, Lundin F, Johansson R, Budzianowska A, Roos AK, K\u00e5gstr\u00f6m V, Gunnarsson M, Sundstr\u00f6m P, Piehl F, Brauner S (2021) Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG Study. Neurology 97(14):e1382\u2013e1391","journal-title":"Neurology"},{"issue":"11","key":"10272_CR23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: The RINOMAX randomized clinical trial. JAMA Neurol 79(11):1105\u20131112","journal-title":"JAMA Neurol"},{"issue":"4","key":"10272_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB et al (2016) International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 87(4):419\u2013425","journal-title":"Neurology"},{"issue":"1","key":"10272_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamaneurol.2020.5407","volume":"78","author":"T Sharshar","year":"2021","unstructured":"Sharshar T, Porcher R, Demeret S, Tranchant C, Gueguen A, Eymard B, Nadaj-Pakleza A, Spinazzi M, Grimaldi L, Birnbaum S, Friedman D, Clair B, MYACOR Study Group (2021) Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial. JAMA Neurol 78(1):426\u2013433. https:\/\/doi.org\/10.1001\/jamaneurol.2020.5407","journal-title":"JAMA Neurol"},{"issue":"6","key":"10272_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X et al (2021) Telitacicept as a BLyS\/ APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43(6):666\u2013673","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10272_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893\u2013902","journal-title":"Eur J Neurol"},{"key":"10272_CR28","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"Vissing J, Jacob S, Fujita KP et al (2020) \u201cMinimal symptom expression\u201d in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267:1991\u20132001","journal-title":"J Neurol"},{"key":"10272_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","volume":"18","author":"S Wang","year":"2018","unstructured":"Wang S, Breskovska I, Gandhy S et al (2018) Advances in autoimmune myasthenia gravis management. Expert Rev Neurother 18:573\u2013588","journal-title":"Expert Rev Neurother"},{"key":"10272_CR30","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","volume":"159","author":"X Yao","year":"2021","unstructured":"Yao X, Ren Y, Zhao Q et al (2021) Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci 159:105704","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10272_CR31","doi-asserted-by":"publisher","first-page":"e16322","DOI":"10.1111\/ene.16322","volume":"31","author":"J Yin","year":"2024","unstructured":"Yin J, Zhao M, Xu X, Zhang M, Xu Z, Li Z, Qin X, Li Z, Zhao C, Zhou H, Ma Y, Cao W, Wang G, Lin Y, Zhang J, Zhang X, Cai H, Qian W, Wang Y, Zhang X, Liu G, Wang J, Qiu W, Min L, Li J, Deng H, Chu L, Zhang Y, Fang J (2024) A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol 31(8):e16322","journal-title":"Eur J Neurol"},{"key":"10272_CR32","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22438.1","author":"S Yung","year":"2020","unstructured":"Yung S, Yap DY, Chan TM (2020) A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.22438.1","journal-title":"F1000Res"},{"key":"10272_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12036-y","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang Z, Du X, Huang X, Zhang Y (2023) Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report. J Neurol. https:\/\/doi.org\/10.1007\/s00415-023-12036-y","journal-title":"J Neurol"},{"issue":"8","key":"10272_CR34","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jcph.686","volume":"56","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Chen X, Hou Y et al (2016) Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol 56(8):948\u2013959","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10272_CR35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12883-021-02439-7","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao S, Zhang K, Ren K et al (2021) Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study. BMC Neurol 21(1):428. https:\/\/doi.org\/10.1186\/s12883-021-02439-7","journal-title":"BMC Neurol"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-025-10272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-025-10272-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-025-10272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T18:06:52Z","timestamp":1767463612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-025-10272-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10272"],"URL":"https:\/\/doi.org\/10.1007\/s11481-025-10272-9","relation":{},"ISSN":["1557-1904"],"issn-type":[{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of The First Affiliated Hospital of China Medical University (protocol number 2023\u2013518-2). It was carried out in line with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval Statement"}},{"value":"All gMG patients gave written informed consent for study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"2"}}